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No evidence for rare recessive and compound
heterozygous disruptive variants in schizophrenia
Douglas M Ruderfer1,2,3, Elaine T Lim4, Giulio Genovese3, Jennifer L Moran3, Christina M Hultman5,
Patrick F Sullivan6, Steven A McCarroll3,7, Peter Holmans8, Pamela Sklar1,9 and Shaun M Purcell*,1,2,3,4
Recessive inheritance of gene disrupting alleles, either through homozygosity at a specific site or compound heterozygosity,
have been demonstrated to underlie many Mendelian diseases and some complex psychiatric disorders. On the basis of exome
sequencing data, an increased burden of complete knockout (homozygous or compound heterozygous) variants has been
identified in autism. In addition, using single-nucleotide polymorphism microarray data, an increased rate of homozygosity by
descent, or autozygosity, has been linked to the risk of schizophrenia (SCZ). Here, in a large Swedish case-control SCZ sample
(11 244 individuals, 5079 of whom have exome sequence data available), we survey the contribution of both autozygosity and
complete knockouts to disease risk. We do not find evidence for association with SCZ, either genome wide or at specific loci.
However, we note the possible impact of sample size and population genetic factors on the power to detect and quantify any
burden that may exist.
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INTRODUCTION
Schizophrenia (SCZ) is a highly heritable (h2 ~ 0.6–0.8), debilitating
disorder with an increasing number of implicated genetic loci1–7 from
genome-wide association studies (GWAS) of common single-
nucleotide polymorphisms (SNPs) and rare copy number variants
(CNVs). Recently, large-scale exome-sequencing studies have searched
for rare variants that strongly increase risk,8,9 although the relatively
high baseline rate of rare neutral coding variation makes this
challenging.10 To focus on rare variants that are a priori more likely
to be highly penetrant for disease, one approach is to study de novo
mutations, as these are effectively uncensored by selection pressures.11
A second strategy, adopted here, is to focus on the rare gene-disruptive
variants, defined as nonsense, essential splice site or frameshift, where
both copies of a gene are affected through homozygosity at a single site
or compound heterozygosity (if an individual carries different
disruptive variants on both the maternally and paternally derived
copies of the gene). With respect to any one gene, we refer to these as
‘complete knockout’ variants. A recent study in autism reported
complete knockout variants at a rate of 1 for every 20 healthy
individuals (0.05 per person) with a twofold higher rate in cases.12
Whereas sequencing allows for direct discovery of rare complete
knockout genotypes, rates of autozygosity (homozygosity by descent)
can also be informative under recessive models. Previous studies have
used SNP microarrays to identify multi-megabase runs of homo-
zygosity (ROH), that likely reflect autozygosity arising from a degree of
recent inbreeding.13,14 A study of 9388, predominantly European, SCZ
cases and 12 456 controls demonstrated a significant positive
correlation between the extent of ROH per individual and the disease
risk.15 However, they did not identify any significant individual loci.
Here we apply both approaches in a large Swedish population-based
sample8,16 of SCZ cases and controls: we first test the recessive model
indirectly by comparing the SNP-derived ROH burden in cases versus
controls, and second, we use exome sequencing to assess directly the
burden of complete knockout variants.
METHODS
Sample ascertainment and data generation
Samples were collected from national registers in Sweden, cases were identified
through the Swedish Hospital Discharge Register and controls were randomly
selected from Swedish population registers. All subjects were appropriately
consented and the Institutional Human Subject Committees approved the
research. Sequencing was performed at the Broad Institute using Illumina (San
Diego, CA, USA) GAII or HiSeq2000 machines. Exome capture was done using
either version 1 or version 2 of the Agilent (Santa Clara, CA, USA) SureSelect
Human All Exon Kit. Additional detail on sample ascertainment and sequence
data generation has been previously published.8 BAM and VCF files are
available in the dbGaP study phs000473.v1 (http://www.ncbi.nlm.nih.gov/
projects/gap/cgi-bin/study.cgi?study_id=phs000473.v1.p1).
Runs of homozygosity calling
We utilized previously published16 SNP imputation data of the entire Swedish
data set representing a superset of the individuals that have been sequenced. We
selected ~ 55 k SNPs in approximate linkage equilibrium from high-quality
genotypes called from imputed dosages in 5001 cases and 6243 controls. We
sought to detect ROH using PLINK17 with parameter settings ROH length
41Mb, at least one SNP per 100 kb and allowance of a single heterozygous
event within a window of 50 SNPs, splitting calls if spanning 500 kb with no
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marker. This method and parameter selection represents those suggested in the
literature after a careful comparison18 and is very similar to the approach used
previously on a subset of these data.15
Compound heterozygous identification
To evaluate the role of complete knockout variants in SCZ we implemented
a method to identify these variants within the framework of the statistical
package Plink/Seq (http://research.mssm.edu/statgen/software.html). The
method analyzes each transcript independently, ensuring that both the
disruptive variants are affecting the same protein. As most pairs of variants
will not be within the distance necessary to phase (length of sequencing read),
we employed a previously used statistical phasing approach to identify
compound heterozygous events.12 We defined compound heterozygosity as
an individual carrying a heterozygous genotype on each chromosome at
different locations within the same gene.
Assessing significance using permutation
Significance of complete knockout variants was assessed by permuting
individual alleles independently assuming Hardy–Weinberg equilibrium
(HWE). Permutation was performed within 296 groups of individuals matched
on IBS from GWAS data to control for subtle population substructure (average
number of individuals per group= 17). We assessed the significance of gene sets
by summing across multiple variants assuming independence.
RESULTS
Among 5001 cases and 6243 controls, we identified 4117 ROH in 2001
individuals; 16% of individuals carried at least one ROH. The average
length of ROH was 8Mb (median length of 6.8Mb) and ranged from
1.6 to 55.2Mb. We also quantified each individual’s genome-wide
degree of homozygosity using Wright’s inbreeding coefficient (F).
After including the first 10 multidimensional scaling (MDS) compo-
nents to account for ancestry, homozygosity was similar in cases and
controls as assessed by the number of ROH (0.38 cases, 0.32 controls,
P= 0.60), total kilobases of ROH (3123 kb cases, 2544 kb controls,
P= 0.88) or F (0.0026 cases, 0.0029 controls, P= 0.09, Table 1).
We next looked for complete knockout variants in a subset of 2477
cases and 2481 controls for whom exome sequence data were
available.8 We identified 462 complete knockout rare (minor allele
frequency o5%) genotypes at 193 genomic locations, a rate of 0.09
per person with no increased burden in cases (229 case; 233 control,
Table 2). Of these, 405 were homozygous and 57 were compound
heterozygous, with no significant enrichment in either class. Analysis
of nonsynonymous and silent complete knockout variants yielded
similar null results (data not shown).
Testing each site individually for association with increased risk
(one-sided), 30 (16%) had Po0.05 but none surpassed the Bonferroni
correction for multiple testing (Supplementary Table S1). This excess
of nominally significant tests is a product of testing only those sites
carrying at least one complete knockout genotype: simulating null
genotype data under HWE using the observed allele frequencies, we
found a similar proportion of nominally significant sites when
following a similar analytic procedure (data not shown).
For the X chromosome, males and females were analyzed separately.
A single hemizygous disruptive variant in males results in a complete
loss of gene function as in the autosomal complete knockout scenario.
Using a minor allele frequency cutoff of 0.25%, we observed 49
disruptive sites outside of the pseudoautosomal regions, a burden of
41 in cases and 41 in controls (one sided Fisher’s exact test P= 0.5).
No individual site achieved nominal significance (Supplementary
Table S2).
Finally, we selected gene sets previously demonstrated to have a
significant polygenic burden of rare disruptive alleles (primarily
observed as a single heterozygous genotype) in the same set of
individuals.8 Across 2546 genes in seven sets, we identified 35
complete knockout or male X chromosome disruptive genotypes, 19
in cases and 16 in controls (P= 0.38; Supplementary Table S3).
Although the set of genes carrying disruptive de novo alleles in SCZ
displayed nominal significance (4:0, one-sided P= 0.027), this does
not survive correction for the seven tests. We also considered genes
with known syndromic autosomal recessive causes of autism or
intellectual disability.19 Three case genotypes and five control geno-
types were found across 119 intellectual disability genes and one case
genotype and zero control genotypes were found across 28 autism
genes; neither test reached nominal significance (P intellectual
disability= 0.72, P autism= 0.57).
DISCUSSION
Overall, we did not observe a significant enrichment of ROH in SCZ
cases. In a larger sample (21 844), Keller et al.15 reported a significantly
higher burden of ROH in SCZ cases, suggesting that the current study
may be under-powered. We note that the Keller et al. study included a
small proportion of the Swedish individuals reported here, although
the authors did not find evidence for increased ROH in the Swedish
subset, consistent with our results. This suggests that population
genetic and ancestry characteristics of a sample could be a further
determinant of the relative role of rare recessive variants in the risk
for SCZ.
The amount of recent inbreeding will contribute to the levels of
homozygosity present in a population. Our sample was ascertained
from Sweden, but includes a proportion of individuals of Finnish
descent. Utilizing populations with recent inbreeding will increase the
frequency of these events and the power to detect enrichment, an
approach that has been used successfully for CNVs.20
In conclusion, this sample does not lend support for a major role of
disruptive recessive or compound heterozygous variants in the risk
of SCZ. There was no overall burden of ROH genome wide or of
complete knockout variants exome wide, no specific genomic site was
significantly associated and no gene achieved significance after
correction. These results largely mirror those of de novo SCZ trio
studies (Fromer et al.11), in which there is no significantly increased
Table 1 Summary of ROH and inbreeding coefficient (F) in full
Swedish GWAS sample, P-values are from a logistic regression with
10 MDS components and wave as covariates
Cases Controls P-value
N 5001 6243
ROH rate 0.38 0.32 0.60
ROH (kb) 3123 2544 0.88
F 0.0026 0.0029 0.09




Compound heterozygous 29 28
All two-hit 229 233
Rate 0.09 0.09
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burden overall and very few individual genes are unambiguously
implicated, although for de novo mutations, broader effects can be
seen across subsets of functionally-related genes. Rare recessive and
compound heterozygous sites may still have a role in disease risk
although larger samples or different analytic approaches may be
required.
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